New Independent Data Further Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) Over Surr...
September 17 2018 - 8:30AM
Daxor Corporation (NYSE MKT:
DXR), an investment company with innovative medical
instrumentation and biotechnology operations focused on blood
volume measurement, today announced the presentation of two Mayo
Clinic studies showing that direct blood volume analysis provides
doctors with important information to inform treatment, and does so
at an advantage over surrogate measurements, including cardiac
filling pressure and kidney function. The studies were presented
Saturday, September 15, 2018 at the 22nd Annual Scientific Meeting
of the Heart Failure Society of America (HFSA) in Nashville, Tenn.
“In each study, we compared blood volume analysis to a surrogate
marker to understand the best way to treat heart failure and, in
one study, heart failure with accompanying kidney disease. Both
studies demonstrated that accurate blood volume measurement
provided important information for physicians to better treat
individual cases of fluid overload and potentially reduce
additional complications,” said Wayne L. Miller, M.D., Ph.D., Mayo
Clinic, who was the lead author of both studies. “Both of these
posters underscore the value of accurate blood volume measurement
as a means of reducing mortality in this complex to treat patient
population.” One poster, “Volume and Pressure in Heart Failure –
Complimentary, But Not Two Sides of the Same Coin,” showed the
distinction between blood volume analysis and cardiac volume
pressure (CVP), which is a surrogate marker for fluid volume
expansion and overload in heart failure patients. The study
concludes that while both demonstrate value, there is no substitute
for clear measurement of fluid volume, as CVP does not accurately
reflect volume status, and therefore should be an additional
measure to blood volume analysis rather than a substitute when
making treatment decisions in heart failure patients with potential
volume overload. The second poster, “Volume-Kidney Interaction in
Chronic Heart Failure – Impact of Subclinical Volume Expansion and
Chronic Kidney Disease on Clinical Outcomes,” showed that blood
volume has a direct connection with kidney function, demonstrating
additional risk in patients with both heart failure and impaired
kidneys. Use of the BVA-100 provided investigators with accurate
plasma volume measurement in order to assess total risk.
“We continue to receive support from the medical
community that reflects our long-held conclusion that direct blood
volume measurement in the heart failure setting is vital to
establishing personalized and optimized treatment,” said Michael
Feldschuh, CEO of Daxor Corporation. “These two posters, which were
independently presented from one of the leading medical
institutions at the preeminent heart failure conference in the
United States, clearly demonstrate the BVA-100 as the most accurate
means to establish blood volume in these circumstances, and to help
physicians best determine treatment options to optimize
outcomes.”
About Daxor Corporation Daxor
Corporation is an innovative medical instrumentation and
biotechnology company. The company manufactures the BVA-100 Blood
Volume Analyzer, the first instrument approved by the FDA to
provide rapid direct measurement of a patient’s blood volume. Daxor
believes that the BVA-100 Blood Volume Analyzer has the potential
to transform therapy in a broad range of surgical and medical
conditions. It is the company’s goal, working in conjunction with
hospitals and clinics, to achieve that possibility. Ultimately, its
mission is to help hospitals and physicians incorporate Daxor’s
BVA-100 diagnostic to significantly improve the quality of patient
care. For more information please visit Daxor’s website at
http://www.daxor.com.
Forward-Looking
StatementsCertain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Daxor Corporation:
Soren Thompson
Investor Relations
212-330-8502
sthompson@daxor.com
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner
CORE IR
561-479-8566
brets@coreir.com
Media:
Jules Abraham
CORE IR
917-885-7378
juleas@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Sep 2023 to Sep 2024